Toward the validation of functional neuroimaging as a potential biomarker for Alzheimer's disease: implications for drug development.
Despite investments carried out in the research since Alzheimer's disease (AD) was firstly defined as an isolated clinical entity, there is still a lack of appropriate cure and effective therapies to halt or slow the disease progression. While fundamental research has provided a better characterization of AD, much remains to be done for the development of new biological treatment strategies. It is now being debated whether functional neuroimaging (FNI) could help improve diagnostic accuracy and become a possible biomarker of AD. The primary purpose of this review was to determine whether data already published in the literature meet formal technology assessment standards for using regional cerebral blood flow (rCBF) or glucose metabolism (rCMRGlu) as a biomarker for AD. The secondary purpose was to identify any remaining gaps that might need to be systematically addressed before drug developers and regulators accept FNI as a biomarker for AD. The present paper reviews the literature regarding metabolic positron emission tomography (PET) and perfusion single photon emission computed tomography (SPECT) studies in AD. There is evidence that treatment with acetylcholinesterase inhibitors (AChEI) leads to changes in brain physiology within the brain regions critical to AD pathology, i.e. the temporal, parietal and frontal association cortex. However, a thorough analysis combining functional and neuropsychological data has not yet been attempted, and much research is needed to validate the role of FNI as a surrogate endpoint for AD clinical trials.
Pupi
Alberto
A
Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Viale Morgagni 85, 50134, Florence, Italy. a.pupi@dfc.unifi.it
Mosconi
Lisa
L
Nobili
Flavio M
FM
Sorbi
Sandro
S
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D015415:Biomarkers; D018450:Disease Progression; D006801:Humans; D049268:Positron-Emission Tomography; D016896:Treatment Outcome
D015415:Biomarkers